AstraZeneca

Aprea bets seven new trial sites on two partial responses in 28 patients

The evidence behind the expansion is two partial responses and six stable diseases among 28 heavily pretreated patients, with both detailed responders carrying a PPP2R1A mutation. The point of adding sites is to find out whether that pattern holds.